Brief: Epirus Biopharmaceuticals initiates phase 3 clinical study
09/02/2016 12:01
Feb 9 (Reuters) - EPIRUS Biopharmaceuticals Inc EPRS.O : * Initiates pivotal global phase 3 clinical study for bow015 (infliximab biosimilar) * Epirus is targeting a harmonized global filing for marketing approval for bow015 in 2017 based on 30-week data * Source text for Eikon urn:newsml:reuters.com:*:nGNXMMGTAa * Further company coverage EPRS.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Epirus Biopharmaceuticals
See all newsBrief: Epirus Biopharmaceuticals entered settlement satisfaction amendment with Livzon Mabpharm
Brief: Jennison Associates dissolves passive stake in Epirus Biopharmaceuticals
Brief: Epirus Biopharmaceuticals enters term sheet with Zaklady Farmaceutyczne
Brief: Epirus Biopharmaceuticals announces reprioritization of pipeline
Brief: Epirus biopharmaceuticals files for non-timely 10-k - sec filing